Q-omics provides the consensus-scored RPL13P5 profile across patient tissues and cancer cell-line models. RPL13P5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPL13P5 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, RPL13P5 RNA expression shows 19,715 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where RPL13P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL13P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL13P5 survival associations across molecular data types. RPL13P5 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL13P5 RNA expression–survival associations across cancer types. High RPL13P5 expression shows unfavorable associations in UVM, LIHC, MESO and ACC, but favorable associations in SKCM and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UVM as the clearest survival context for RPL13P5 RNA expression.
This table summarizes RPL13P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL13P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL13P5 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRP, LIHC, STAD and COAD. The HNSC box plot shows higher RPL13P5 RNA expression in tumor versus normal tissue (log2 FC = +0.794, t-test p < 0.001).
This table shows molecular features associated with RPL13P5 in patient tissues and cancer cell lines. In patient samples, RPL13P5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
